Avanza Fonder’s Ionis Pharmaceuticals IONS Stock Holding History

Avanza Fonder’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,596	Closed	-$284K	–	497
2025 Q4	$284K	Buy	+3,596	New	+$271K	0.01%	412

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avanza Fonder's IONS Position: Q1 2026 in Review

Avanza Fonder sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 3,596 shares — an estimated $284K sold.

Avanza Fonder first reported a position in IONS in Q4 2025 and held it in 1 quarter. The position peaked at $284K in Q4 2025. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Avanza Fonder reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Avanza Fonder sold 3,596 Ionis Pharmaceuticals shares in Q1 2026, an estimated $284K.
Avanza Fonder first reported a position in Ionis Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Avanza Fonder's Ionis Pharmaceuticals position peaked at $284K in Q4 2025.
494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Avanza Fonder's 13F filing for Q1 2026, filed 15 Apr 2026.